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Abstract 
 
 
Objective: To determine whether the type of practice to which physicians belong 
influences the types of medications they prescribe 
Methods: The study used data from the National Ambulatory Medical Care 
Survey (NAMCS) to conduct a series of regressions for two pairs of medications. 
The first pair was for the treatment of high cholesterol. Advicor was the new 
medication and Lovastatin was the competitor. The second pair was for the 
treatment of arthritis. Humira was the new medication and Remicade was the 
competitor. For each pair, there were two sets of regressions that consisted of an 
unrestricted regression with all patients in the sample and a restricted regression 
limited to recipients of the two medications.  
Results: The results of the study showed solo physicians were more likely to 
prescribe Advicor over Lovastatin, but less likely to prescribe Humira over 
Remicade.  
Conclusions: The study suggests there is a difference present in the prescriptions 
written in solo versus group physicians and additional factors dealing with the 
specific drug must determine the direction of this difference. 
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Introduction 
 
 This study explores whether the type of practice to which physicians 
belong influences the types of medications they prescribe. The type of practice is 
defined here as a solo practice or a group practice. A group practice consists of 
two or more physicians, with HMOs eliminated for consistency. In particular, I 
hypothesize that solo practice doctors might be less likely than group practice 
doctors to adopt new medications because, as owners, they face greater workloads 
and administrative burdens and are less exposed to peer consultation.  The 
estimates presented in this paper can help to provide patients and health care 
professionals with information about how the choice of one doctor or another can 
affect treatment. 
 There is consistent agreement in the literature regarding the general 
benefits and consequences of solo and group practices. Solo practitioners lack 
peer consultation and ease of information sharing.
1,2
 Solo physicians report severe 
job constraints such as a heavy workload, out of hours calls, and administrative 
burden.
3
 Administrative issues have become too extensive to handle without staff 
assistance and multiple physicians.
4
 Group practice can help alleviate these 
disadvantages, but solo practice physicians most frequently cite difficulty with 
cooperation and autonomy as a barrier to joining a large medical group.
5
 Group 
practice also entails constant scrutiny, stricter adherence to quality and procedure, 
a sacrifice of professional status and a decreased possibility of earning a high 
income.
6
 Interestingly, a 2000 study did report that the time pressure ratio was the 
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lowest with solo practitioners when compared with groups. Solo practitioners also 
seemed to spend the least amount of time stressed.
7
  
To analyze the effect of the type of practice on the types of medications 
prescribed, the data for this study was taken from the National Ambulatory 
Medical Care Survey (NAMCS). I selected two pairs of prescription for my 
analysis: Lovastatin and Advicor (the “new” medication) are prescribed for high 
cholesterol; Remicade and Humira (the “new” medication) are commonly 
prescribed to treat rheumatoid arthritis. The prescriptions were chosen based on 
the criteria that were intended for a very common diagnosis in order to ensure a 
large sample size, the new medication had to be made available within the years 
1997 and 2007 in order to be able to document a change within my dataset, and 
the medication could not be a completely new invention because there needed to 
be a commonly prescribed competitor for comparison.  
Each pair of medications has two step-wise linear regression sets. The 
regressions estimate if there is a significant difference in the prescribing behavior 
of group and solo physicians for two different dependent variables measuring 
when the new medication was introduced: The first regression set is with an 
unrestricted sample where the dependent variable represents if a prescription was 
written for either medication to show if there is some difference between solo and 
group physicians that is inherent in the conditions themselves; the second 
regression set is a restricted sample where the dependant variable is the new 
medication.  
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The study did indicate some possible bias. The standard errors were high, 
especially for the Humira-Remicade set.  In addition, the values showed some 
consistent variation across the step-wise linear restricted regressions, so there is a 
possibility that the effects are conservative due to a missing control. Group 
practices were not divided further to delineate small groups from large medical 
groups. Group practices were also not separated as single-specialty or multi-
specialty groups. Such distinctions would be useful in providing more distinctive 
data concerning practice type. A log-regression function may be used in the future 
to get a more accurate assessment of the effects that were measured. Further 
research is necessary to confirm these findings and take the next step towards 
tempering differences in the healthcare system. 
 The results of the study showed there was a non-significant effect of the 
two conditions on solo and group practice behavior. There was a positive effect 
for Advicor after the approval date, indicating solo physicians were more likely to 
prescribe Advicor over Lovastatin. Interestingly, there was a negative effect for 
Humira after the approval date, indicating solo physicians were less likely to 
prescribe Humira over Remicade. The study suggests there is a measurable 
difference present in the prescribing behavior of solo versus group physicians 
when a new medication enters the market. However, additional factors special to 
the specific drug must determine the direction of this effect. One possible 
explanation for the discrepancy is Advicor incorporates Lovastatin plus a second 
drug together and purchasing one medication is cheaper than purchasing two 
separate ones. 
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The paper will progress in the following manner. The key institutional 
factors will discuss necessary basic facts concerning solo practice, group practice, 
and the medications involved in the study. Then there is a description of the 
dataset and some descriptive results. The next section is a presentation of the 
model followed by the results of the study. Lastly, the paper finishes with some 
concluding thoughts. The preliminary graphs are in the Figures section in the 
‘Appendices’ at the end of the paper, followed by a descriptive table and 
regressions. 
 
Key Institutional Factors 
 Solo vs. Group Practice 
A discussion of group and solo practices is highly relevant. The latest data 
made available by the Bureau of Labor Statistics reports approximately 12% of 
physicians and surgeons were self-employed.
8
 An important voice for medical 
group practices since its conception in 1926, the Medical Group Management 
Association (MGMA) defines a group practice as a “formal organization or legal 
entity of three or more physicians that share business and clinical facilities, 
records, and personnel.”
9
 The American Medical Association reported growing 
national numbers of group practices in 2003.
10
 In 2007, the Department of Health 
and Human Services published a report of their own that supported and further 
explored these figures. The report found that in 2003-2004, “35.8 percent of 
physicians were in solo practices, 43.1 percent were in single-specialty group 
practices, and 21.1 percent were in multi-specialty group practices.” In addition, 
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74.9% of “office-based physicians owned or were part owner of their practice.”
11
 
These statistics illustrate the prevalence of group and solo practices and support 
my hypothesis that ownership status may be an important factor that influences 
prescribing behavior.  
 
Selection of Prescriptions 
There are two pairs of prescriptions examined in this study. The first pair 
includes Advicor and its predecessor Lovastatin, both prescriptions for high 
cholesterol. The National Health and Nutrition Examination Survey reported that 
in 2005-2006, 16% of adults had total cholesterol levels of 240 mg/dL or greater. 
These cholesterol levels are in the high-risk category for heart disease. Although 
the percent of adult screening has increased, 8% still have been found to have 
high cholesterol, but had not been diagnosed by a doctor.
12
 A Morbidity and 
Mortality Weekly Report claimed a 10% decrease in total cholesterol levels might 
result in an estimated 30% reduction in the incidence of coronary heart disease.
13
  
Lovastatin, with brand names Mevacor and Altoprev, is a cholesterol-
reducing HMG-CoA reductase inhibitor.
14
 Like other statins, Lovastatin lowers 
total bad cholesterol and increases good cholesterol in order to help slow coronary 
artery disease.
18
 Advicor was the first drug to combine Lovastatin with Niacin 
into a single oral drug for lowering cholesterol. It is the same medication, but it is 
new in that it allows patients to only buy one prescription instead of two.
15
 
Advicor was approved by the FDA in 2001 and appears in the sample in 2002.  
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The second pair of drugs includes Humira (adalimumab) and its 
predecessor Remicade (infliximab), both prescriptions for rheumatoid arthritis. A 
2007 study in the American Journal of Medicine cited that an estimated 25 men 
and 54 women per 100,000 in the population are afflicted with rheumatoid 
arthritis, making it the most common inflammatory arthritis. The article also 
included a statistic stating it was responsible for 250,000 hospitalizations and 9 
million physician visits in the U.S. each year.
16
 The National Institute of Arthritis 
and Musculoskeletal and Skin Diseases publishes a handout that claims 1.3 
million adults, or 0.6% of the U.S. population, suffer from rheumatoid arthritis. 
This number is low when compared to previous estimates due to a recent re-
defining of the condition, but still encompasses over 1 million people.
17
  
Both Humira and Remicade are medications known as TNF-alpha 
blockers. TNF-alpha is a protein that can cause pain and inflammation as well as 
severe joint damage.
18
 The FDA approved Remicade, the second TNF inhibitor, 
in 1999. The drug uses a combination of human and mouse proteins to create a 
monoclonal antibody. Humira is different because it is the first fully human 
monoclonal antibody.
16
 The other important difference between Humira and 
Remicade deals with administration of the drug. Humira is self-administered as a 
biweekly subcutaneous injection whereas Remicade is an intravenous infusion 
only provided in the physician’s office.
19
 The first instance of Humira in the 
sample is in 2005 indicating a possible sample error as the FDA approved it a few 
years earlier. This discrepancy in time period is most likely a failure in the survey, 
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but is not expected to drastically skew results because two full years of data are 
still available for an accurate comparison. 
 
Description of Data 
 Data Sources 
 My data is taken from the National Ambulatory Medical Care Survey 
(NAMCS).  NAMCS is a national survey of a sample of visits to physicians that 
provide direct patient care on an outpatient basis. The specialties of 
anesthesiology, pathology, and radiology were excluded. The survey was 
conducted annually from 1973 to 1981, 1985, and every year after 1989. Data was 
collected from the physician over a randomly assigned one-week reporting 
period.
20
 The data provides a patient weight in order to be able to extrapolate the 
findings of the sample to a national estimate.  
 My study will utilize the specific years of 1997-2007 because these years 
have the most detailed information on patient characteristics, physician 
characteristics, and from six to eight medications prescribed. With regard to 
patient characteristics, I have included the number of co-morbidities, the number 
of total medications prescribed, age, sex, race, and insurance. Physician 
characteristics were region, location in a metropolitan area, descriptors of the 
patient-physician relationship, descriptors of the visit, and employment status. 
These selections were made because they were the most consistently present in 
the data and are likely to have a possible effect on outcome. 
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Descriptive Results 
 The preliminary charts and graphs reveal a few interesting points about the 
sample.  Figure 1 shows a graph for each pair of drugs; panel A shows the 
numbers of prescriptions of the cholesterol drugs, Advicor and Lovastatin, by 
year, and panel B shows the numbers of prescriptions of Humira and Remicade, 
the arthritis drugs, by year.  The dashed line represents the new medication in 
both panels and the solid line represents the older competitor. Both y-axes are 
weighted to represent the national estimate. The x-axis for the Humira and 
Remicade graph begins with the year 2000 due to the availability of data in the 
sample. 
Panel A shows the introduction of Advicor to the sample in 2002 and 
illustrates how vastly popular Lovastatin was, even after the introduction of 
Advicor. There is a sharp and mostly continuous increase in Lovastatin starting in 
2002 that peaks at over 5,000,000 annual prescriptions. There is also a steady 
upward trend in Advicor, but at a slower rate than Lovastatin. In Panel B of 
Figure 1, there is an observable drop in prescriptions for Humira in 2006 that is 
most likely the result of a problem with the sample. Unlike Humira’s jagged 
increase, Remicade steadily increases to around 900,000 annual prescriptions with 
the exception of one drop from 550,000 to 200,000 annual prescriptions in 2002 
to 2003.  
 Figure 2 shows the number of prescriptions that were written in solo or 
group practices, clinics or urgicenters, health or mental health centers, family 
planning clinics, HMOs, and other practice types. Figure 2 is divided into two 
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panels: panel A shows the prescriptions written for Lovastatin vs. Advicor and 
panel B shows the prescriptions written for Remicade vs. Humira. Both panels are 
organized in a horizontal bar graph with the darker bar representing the newer 
medication. The x-axis was weighted to represent the national estimate.  
 Panel A and panel B both maintain that the majority of prescriptions 
written were in ‘Solo and Group’ practices. In panel A, there were about 
4,000,000 prescriptions written in HMOs, but these were excluded given the 
almost 14,000,000 prescriptions written for Lovastatin in ‘Solo or Group’ and the 
fact that none of the other medications appeared in significant numbers for HMOs 
in the sample. Therefore, in order to simplify the regression and obtain the 
clearest results, group practices were isolated from HMOs and the term ‘Non-
Solo’ in this study should be taken to mean a group practice of two or more 
physicians. There was a comparatively small number of prescriptions written for 
Lovastatin in the clinic/urgicenter, health or mental health center, and other 
practice types. In panel B, there were similarly small numbers of prescriptions 
written for Remicade in the clinic/urgicenter and health or mental health practice 
types. For the solo or group practice type, Remicade was measured at around 
2,750,000 prescriptions and there were almost 1,000,000 prescriptions for 
Humira. Since the majority of prescriptions were written in solo or group 
practices, the data supports my decision to focus the analysis of this study on 
these two types.  
 Figure 3 further illuminates the sample size of the study in that it shows 
the estimated number of prescriptions that were written nationally in a solo versus 
 
 
10  
non-solo practice. The figure is organized as a vertical bar graph divided into four 
sections along the horizontal axis for each prescription. Each section contains two 
bars each for solo and non-solo practice types, with the darkest bar representing 
solo practices. Figure 3 includes a patient weight variable to be representative of 
the national estimate.  
 Every drug had significantly more prescriptions written in a non-solo 
setting, especially for Lovastatin. Lovastatin is clearly the largest in the sample 
for both types of practices with just over 14,000,000 prescriptions written in a 
non-solo practice and almost 4,000,000 prescriptions written in a solo practice. 
While Lovastatin is the largest in the sample, the prescriptions written for 
Advicor, Remicade, and Humira were similar in number and estimated at between 
around 500,000 and 2,000,000. Even Humira with the fewest prescriptions had a 
sample size of hundreds of thousands of prescriptions over the years based on the 
y-axis scale of 2,000,000. 
 Figure 5 is a series of four panels that shows the number of solo and non-
solo practices in the sample that prescribed the medications each year. Panel A is 
a graph illustrating the breakdown of solo and non-solo practices prescribing 
Lovastatin; panel B is a similar graph for Advicor; likewise, panel C depicts 
Remicade and panel D, the final graph, depicts the practices prescribing Humira. 
In each panel, the dashed line represents the solo practice. Unlike the previous 
figures, Figure 5 is a pure description of the sample itself without weights.  
 Panel A (Lovastatin) shows an upward trend similar to the number of total 
annual prescriptions in Figure 1. Panel B (Advicor) and panel D (Humira) show 
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non-solo practices as significantly more prevalent in the sample. Panel B shows a 
two-tiered increase in non-solo practices with a slight dip between 2003 and 2005. 
The number of solo practices increases dramatically in 2003, but then sees a 
steady decline from 2004 onward. Panel D shows a sharp increase in solo 
practices starting in 2006 and a more jagged increase in non-solo practices 
beginning in 2004. Although panel C (Remicade) has higher values for non-solo 
practices, they track annually in a similar pattern to the solo practice values 
indicating tandem growth with the exception of a sharp jump in 2002 for solo 
practices.   
 The descriptive characteristics table [Table 1] contains sample means for 
solo versus non-solo practices with corresponding t-values in the far right column. 
The standard errors are located in parentheses beneath the sample means. Each 
variable represents a descriptor of the physician or the patient that is relevant to 
the regressions. The variables are divided into six categories of health status, 
demographics, physician descriptors, region, insurance variables, and 
employment. 
 Due to the large sample sizes and the resulting precision of the estimates, 
all the differences are statistically significant, but the differences between solo 
and group practices are not in general large enough or economically important. 
The high t-values also indicate significant similarity between the samples. The 
lack of stark contrast maintains the presumption that the patients treated in solo 
and non-solo practices are similar enough to avoid omitted variable bias in the 
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regression results. It is possible these variables are be a potential source of bias 
that is I will address by adding them as controls in my analysis.  
 
Model 
 In order to properly control for extraneous influences, there are necessary 
characteristics that have to be considered for both the patients and the physicians. 
As in Table 1, these characteristics are split into six different categories as 
follows. Health status controls included the number of co-morbidities and the 
number of total medications prescribed to the patient. These variables were 
chosen because they are proxy measures of health status that could influence 
physician behavior. Demographic controls included age, race, and gender. 
Physician descriptors included the physician’s status as the patient’s primary, 
whether the physician had seen the patient before, whether the patient had contact 
with someone other than the physician such as a physician’s assistant or nurse 
practitioner, and whether the practice was located in a metropolitan area. Region 
fixed effects partition the United States into the Northeast, Midwest, South, and 
the West.  Insurance variables were identified as Medicare, Medicaid, Private 
Insurance, Worker’s Compensation, Self-Pay, and No Charge. Finally, the last 
regression takes the employment status of the physician into account and indicates 
owner, employee, or contractor.   
 To accomplish the goals of the study, I will be utilizing the following 
linear structural model: 
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(1) Prescriptionit = β0 + β1SOLOit + β2SOLOit*I{YEARt>=2002} + 
β3I{YEARt>=2002} + µ´xit + ε 
 For each set, this model is used twice. The binary dependent variable for 
the first regression set is a prescription for either drug in the set, given whether the 
patient visited a solo or group practice in a certain year (SOLOit), whether a 
patient visited a solo practice after the new medication was available 
(SOLOit*I{YEARt>=2002}), whether the year was post-introduction of the new 
medication (I{YEARt>=2002}), and a set of controls that accounted for various 
patient and physician characteristics (µ´xit). For Prescriptionit, a one represented 
receiving either of the two medications and a zero represented all other outcomes. 
Likewise, SOLOit and SOLOit*I{YEARt>=2002} are binaries with a one assigned 
for solo practice and a zero assigned for group practice. Using this model, I will 
be able to take prescription outcomes and isolate its correlation with physician 
practice type, while controlling for other factors. The second regression set 
follows the same model except the binary dependent variable is whether a 
prescription was written for the new or old medication. In this case, the new 
medication was assigned a one and the old medication was assigned a zero. A 
patient weight was used to expand the data to a national estimate.   
 
Results 
 Tables 2 through 4 show the main results of this analysis.  In Table 2, the 
sample includes all cases, and the binary dependent variable is an indicator for 
whether either Lovastatin or Advicor was prescribed in that case.  A one was 
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assigned to the two drugs and a zero was given to all other cases. Each column 
shows results from a different ordinary least squares (linear probability model) 
regression.  In each case, the coefficients of interest are an indicator for solo 
practice, an indicator for Year ≥ 2002, and the interaction of these two variables.  
The specification in column (1) includes those variables and no controls.  In 
column (2), controls for the patients’ health status are added; demographic 
controls are added in column (3); column (4) included physician descriptors; 
region fixed effects are added in column (5); column (6) contains insurance 
controls; column (7), the final column, included all these controls plus the 
addition of employment variables. A step-wise regression table was used in order 
to determine if any one group of controls drastically affected the results. The 
bottom section indicates with a ‘Yes’ term the control categories that were 
included in the regression. The last row is the R
2
 for each regression. 
 In Table 2, the results were mostly consistent across all seven regressions. 
Of all the non-significant measurements in column (7), the most significant 
coefficient was for the year after 2002, which showed a .003. The variable for 
either prescription after 2002 at a solo practice saw a .002 decrease in column (7). 
The solo practice variable saw the biggest amount of variation, but the 
coefficients were so small that it most likely indicates no effect at all. The solo 
variable fluctuated from a -0.0001623 in column (1) to a .0004 in column (7). 
Given these small numbers and the general consistency, it can be determined that 
there was not a significant difference between solo and group physicians for the 
prescribing of high cholesterol that is unrelated to the medications. It further 
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indicates additional controls did not heavily impact the regression and so the 
possibility that an unknown control may drastically sway these results is 
minimized. 
Table 3 restricts the same to cases in which Lovastatin or Advicor was 
prescribed, and the binary dependent variable is an indicator for whether the 
newer drug (Advicor) was the one prescribed. A one indicated Advicor and a zero 
was assigned to Lovastatin. Similar to Table 2, each column shows results from a 
different ordinary least squares (linear probability model) regression. The 
columns add controls progressively in the same manner as Table 2.  
 Table 3 showed some significant indicators. The solo variable for the 
years after 2002 gradually increased from 0.088 in column (1) to .197 in column 
(7), illustrating an increasing effect with additional controls. Likewise, the solo 
variable for all the years steadily decreased from near zero in column (1) to -0.161 
in column (7). Therefore, there is a possibility that the values in the seventh 
regression are still conservative due to some unaccounted for control. The 
adequacy of the model is demonstrated by the R
2
 values. The final R
2
 of .154 in 
column (7) suggests that a log regression may more be a more adequate model. 
The high standard errors also suggest the possibility of an error in the construction 
of the model. The most realistic regression, column (7) shows the positive effect 
of the solo practice variable for the years after 2002 was .197. The negative solo 
variable for all years  (-0.161) may be explained by the fact that Lovastatin was 
vastly popular and continued to be so after Advicor entered the market, even 
though some solo physicians were changing their prescribing behavior. It is also 
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likely that some of the change is due to the fact that one prescription is generally 
less expensive than two prescriptions that are equivalent to Advicor.  
 Table 4 is organized in the same way as Table 2. The dependent variable 
is a binary indicator for whether Humira or Remicade was prescribed, with a one 
representing a prescription for either of the medications and a zero representing 
all other cases. In Table 4, the solo variable for the years after 2005 show a 
largely consistent .00012 across the columns. Solo practice varied from 
0.0000775 in the first column to .00004 in column (7). Finally, the year variable 
stayed completely consistent at .00001. All of these coefficients are non-
significant and although slightly more variable, the small values confirm the same 
conclusions as with the Advicor-Lovastatin set in Table 2. Additional unknown 
controls may cause some results to change, but most likely not to any significant 
amount. There is also no indication that there is any difference between solo and 
group physicians that is a product of the diagnosis and unrelated to the two 
medications. 
 Table 5 restricts the sample to cases in which one of those two drugs was 
prescribed, and the binary dependent variable is an indicator for whether the 
newer drug (Humira) was the one prescribed. In this table, a prescription of 
Humira was assigned a value of one and zero was given to prescriptions for 
Remicade. The organization for Table 5 was the same as the previous regression 
tables. The variation between the regressions in the solo variable was not a steady 
rise or decline, but rather showed some jumps. The effect of a solo practice is .110 
in the fourth column, which is an increase from the previous columns, but by the 
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seventh and most complicated column the effect is at -0.080. The solo variable for 
the years after 2005 does not fluctuate and indicates a significant and large effect 
of -0.233 in column (7). The increasing R
2 
with a value of .528 in the last column 
is an encouraging indicator that this final regression model is a better fit for the 
data, although the standard errors are still high.  
 
Conclusion 
 This study attempted to ascertain whether the type of practice to which 
physicians belong influences the types of medications they prescribe. The study 
used two different pairs of medications: Advicor vs. Lovastatin, and Humira vs. 
Remicade. The study also included a number of controls under the categories of 
health status, demographics, physician descriptors, region, insurance variables, 
and employment status. 
 The results revealed the following conclusions. Solo physicians were more 
likely to prescribe Advicor over Lovastatin, but less likely to prescribe Humira 
over Remicade. Although both sets of prescriptions failed to show the same 
consistent trend, there was a significant difference in prescribing behavior for 
both Advicor and Humira. This suggests that not only is there a difference present 
in the prescriptions written in solo versus group physicians, but that there are 
additional factors regarding the type of drug that determine the direction of this 
difference. One possible explanation for the discrepancy is Advicor incorporates 
Lovastatin plus a second drug together and purchasing one medication is cheaper 
than purchasing two separate ones. Although this study determined an effect on 
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prescribing behavior, it was not designed to identify the actual source of the 
observed effect. This represents a significant gap in our knowledge and 
understanding of the physician-patient relationship.  
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Appendices 
Figures 
Figure 1 – Number of Annual Prescriptions 
Panel A: 
 
 
 
 
 
 
Panel B: 
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Figure 1 has a graph for each prescription pair and shows the number of 
prescriptions written for each drug by year. Both y-axes are weighted to 
represent the national estimate. The x-axis for the Humira and Remicade 
graph begins with the year 2000 due to the availability of data in the 
sample. 
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Figure 2 - Number of Prescriptions in Different Types of Practices 
Panel A: 
 
 
 
 
 
Panel B: 
 
 
 
 
 
 
 
Figure 3 – Estimated Number of Prescriptions Written Nationally In a Solo vs. 
Non-Solo Practice 
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Figure 2 is split into two separate panels due to the significantly higher prevalence of 
Lovastatin. The x-axis was weighted to represent the national estimate. 
Figure 3 breaks the prescriptions written for each medication down into whether they 
originated from a solo or non-solo practice. It should be noted that Figure 3 also 
includes a patient weight variable to be representative of the entire country. 
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Figure 4 – Number of Solo and Non-Solo Practices in Sample That Prescribed 
Medications 
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Figure 4 is a series of four panels, one per medication. Each medication is broken down 
into whether it was prescribed in a solo or non-solo practice by year. There is no weight 
alteration. 
 
23  
Tables 
Table 1 – Descriptive Tables 
  
Table 1 contains sample means for solo versus non-solo practice with corresponding t-
values in the far right column. The standard errors are located in parentheses beneath the 
sample means. 
Solo Non-Solo t
Co-morbidities 0.700 0.660 -11.86
(0.788) (0.799)
Total Medications 1.550 1.760 -25.56
(1.830) (2.094)
Age 47.122 45.497 15.69
(0.080) (0.065)
Female 0.577 0.570 3.30
(0.002) (0.001)
White 0.859 0.867 -5.06
(0.001) (0.001)
Primary Care Physician 0.344 0.372 -13.96
(0.002) (0.001)
Seen Before 0.857 0.853 2.38
(0.001) (0.001)
Saw Physician 0.960 0.975 -18.32
(0.001) (0.000)
Saw Physician's Assistant 0.024 0.024 0.55
(0.001) (0.000)
Saw Nurse Practitioner 0.014 0.010 9.73
(0.000) (0.000)
Metropolitan Area 0.826 0.864 -24.59
(0.001) (0.001)
Northeast 0.237 0.201 20.03
(0.001) (0.001)
Midwest 0.187 0.243 -32.54
(0.001) (0.001)
South 0.361 0.336 12.34
(0.002) (0.001)
West 0.216 0.220 -2.57
(0.001) (0.001)
Private Insurance 0.515 0.591 -35.95
(0.002) (0.001)
Medicare 0.251 0.244 3.78
(0.001) (0.001)
Medicaid 0.111 0.101 8.14
(0.001) (0.001)
Worker's Comp 0.017 0.016 0.78
(0.000) (0.000)
Self Pay 0.097 0.040 50.80
(0.001) (0.001)
No Charge 0.009 0.008 2.28
(0.000) (0.000)
Owner 0.926 0.625 196.10
(0.001) (0.001)
Employee 0.050 0.334 -199.33
(0.001) (0.001)
Contractor 0.024 0.040 -22.65
(0.001) (0.001)
Group 0.000 0.838 -879.90
(0.000) (0.369)
Employment 
Status
Health Status
Descriptive Characteristics
Demographic 
Physician 
Descriptors
Region Fixed 
Effects
Insurance
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Summary 
 
 Healthcare is a system of asymmetrical information. Physicians are trained 
to properly diagnose and treat their patients. Patients, for their part, trust that the 
decisions made by their doctors are appropriate and in their best interest. 
However, healthcare is also a business and it has been well documented that the 
behavior of physicians is influenced by outside factors, in particular the type of 
practice a physician belongs to.   
 This study explores whether the type of practice to which physicians 
belong influences the types of medications they prescribe. The type of practice is 
defined here as a solo practice or a group practice. A group practice consists of 
two of more physicians, with HMOs eliminated for consistency. In particular, I 
hypothesize that solo practice doctors might be less likely than group practice 
doctors to adopt new medications because, as owners, they face greater workloads 
and administrative burdens and are less exposed to peer consultation.  The 
estimates presented in this paper can help to provide patients and health care 
professionals with information about how the choice of one doctor or another can 
affect treatment. 
To analyze the effect of the type of practice on the types of medications 
prescribed, the data for this study is taken from the National Ambulatory Medical 
Care Survey (NAMCS) from which I chose two different pairs of prescriptions. 
The prescriptions were chosen based on the criteria that were intended for a very 
common diagnosis in order to ensure a large sample size, the new medication had 
to be made available within the years 1997 and 2007 in order to be able to 
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document a change within my dataset, and the medication could not be a 
completely new invention because there needed to be a commonly prescribed 
competitor for comparison.  
The first pair I chose was Advicor and its predecessor Lovastatin because 
of the millions of Americans affected by high cholesterol. Advicor was the first 
drug to combine Lovastatin with Niacin into a single oral drug for lowering 
cholesterol. It is the same medication, but it is new in that it allows patients to 
only buy one prescription instead of two. The second pair of medications 
consisted of Humira and its predecessor Remicade, which treat rheumatoid 
arthritis. Arthritis is another extremely debilitating condition with a large-scale 
impact. Humira is different from Remicade because it is a new antibody that 
expands on previous technology. Humira is also administered differently from 
Remicade.  
Each pair of medications has two linear regression sets. The first 
regression set is with an unrestricted sample where the dependent variable 
represents if a prescription was written for either medication. For the Advicor-
Lovastatin pair, the regression had non-significant results and showed there was 
no difference between solo and group practice physicians that was inherent in the 
condition.  The first regression set for the Humira-Remicade pair replicated these 
results. It also found a non-significant effect and confirmed there was no 
underlying selection difference between solo and group practice physicians for 
patients with high cholesterol or arthritis. 
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The second regression set is a restricted sample where the dependant 
variable is receiving the newer of the two medications. For the Advicor-
Lovastatin pair, the regression estimates whether the type of practice influences 
physicians prescribing behavior. The results revealed a positive effect for Advicor 
after the approval date, indicating solo physicians were more likely to prescribe 
Advicor over Lovastatin. Interestingly, the second regression set for the Humira-
Remicade medication pair had different results. This restricted regression showed 
a negative effect for Humira after the approval date, indicating solo physicians 
were less likely to prescribe Humira over Remicade.  
The study did have some flaws. The standard errors were high, especially 
for the Humira-Remicade set.  In addition, the values showed some consistent 
variation across the step-wise linear restricted regressions, so there is a possibility 
that the effects are conservative due to a missing control. Group practices were 
not divided further to delineate small groups from large medical groups. Group 
practices were also not separated as single-specialty or multi-specialty groups. 
Such distinctions would be useful in providing more distinctive data concerning 
practice type. A log-regression function may be used in the future to get a more 
accurate assessment of the effects that were measured. Further research is 
necessary to confirm these findings and take the next step towards tempering 
differences in the healthcare system.  
 In conclusion, solo physicians were more likely to prescribe Advicor over 
Lovastatin, but less likely to prescribe Humira over Remicade. Both sets of 
prescriptions failed to show the same consistent trend, but there was a significant 
 
31  
effect on prescribing behavior measured in each case. This suggests that not only 
is there an difference present in the prescriptions written in solo versus group 
physicians, but that there are additional factors regarding the type of medication 
that determine the direction of this difference. One possible explanation for the 
discrepancy is Advicor incorporates Lovastatin plus a second drug together and 
purchasing one medication is cheaper than purchasing two separate ones. 
Although this study determined an effect on prescribing behavior, it was not 
designed to identify the actual source of the observed effect. This represents a 
significant gap in our knowledge and understanding of the physician-patient 
relationship. 
